Iterum Therapeutics Announces Pricing of Initial Public Offering

Iterum Therapeutics Announces Pricing of Initial Public Offering

DUBLIN and CHICAGO, May 24, 2018 /PRNewswire/ — Iterum Therapeutics plc (NASDAQ: ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today announced the pricing of its initial public offering of 6,150,000 ordinary shares at a price